MVZ am Klinikum Aschaffenburg GmbH
- Address
- Industriestr. 2, 63768 Hösbach, Germany
Breast Cancer (Hormone Receptor‑Positive / HER2‑Negative)
MVZ am Klinikum Aschaffenburg GmbH conducts research on neoplasms with a strong emphasis on breast cancer, ranging from early disease at risk of recurrence to advanced metastatic settings. The trials aim to test new combination therapies, improve survival outcomes, and incorporate digital tools for side‑effect management.
- Evaluation of disease‑free survival in early hormone‑receptor‑positive breast cancer
- Assessment of progression‑free survival in advanced/metastatic patients
- Investigation of treatment persistence with ribociclib therapy
- Integration of digital side‑effect monitoring alongside endocrine therapy
These studies reflect the site’s commitment to advancing care for patients with hormone‑positive, HER2‑negative breast cancer.
Relapsed/Refractory Multiple Myeloma
Within the broader field of neoplasms, the center is evaluating innovative approaches for multiple myeloma that has returned after prior treatment. The focus is on measuring response rates and safety of novel antibody‑drug conjugates combined with standard regimens, aiming to extend durable remission for heavily pre‑treated patients.
- Response rate to belantamab mafodotin–based combination therapy
- Safety profiling in relapsed/refractory disease
- Exploration of extended dosing schedules
- Improving outcomes for patients with limited therapeutic options
The trial underscores the site’s role in bringing cutting‑edge myeloma treatments to the clinical setting.
Locally Advanced Rectal Cancer
The institution also focuses on neoplasms of the gastrointestinal tract, specifically rectal cancer. Research compares pre‑operative chemotherapy strategies and evaluates their impact on surgical success and long‑term disease control, with disease‑free survival as a key endpoint.
- Comparison of FOLFOX neoadjuvant therapy versus risk‑adapted postoperative chemotherapy
- Assessment of surgical margins and recurrence risk
- Monitoring of disease‑free survival across treatment arms
- Optimization of pre‑operative treatment protocols
These investigations aim to refine therapeutic pathways for patients with locally advanced rectal cancer at MVZ am Klinikum Aschaffenburg GmbH.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ am Klinikum Aschaffenburg GmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Atezolizumab with FLOT Versus FLOT Alone in Locally Advanced Resectable Esophagogastric Adenocarcinoma | Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH | Phase IV | Not Recruiting | Sep 2018 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Calcium Folinate Pentahydrate | 2 | Unknown | 2018-09-03 | 2020-09-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.